IgM nephropathy (IgMN) is an idiopathic immune complex-mediated glomerulopathy that was first described as a distinct disease in a nephropathology literature in 1978. Here, a historical review and the current status of IgMN in the light of world literature and the current experience will be presented. The Pubmed (www.pubmed.gov) search was made for articles on IgMN as the sole subject of the study or where it constituted a significant number of cases in a biopsy series in the world literature written in English. A total of 41 articles were found. A critical review of the literature was made. Soon after 1978, a series of reports were published mostly from the western world, but the interest in the entity did not withstand the test of time. No substantial basic medical research was carried out and the disease was largely ignored by the western researchers. More recently, a flurry of articles have appeared in the literature on the topic, mostly from tropical countries, and have renewed the interest in the entity. However, most of the current literature on IgMN is based on clinical observations, and experimental models and mechanistic stud ies of IgMN are lacking. There is an urgent need to develop consensus based criteria for the diagnosis of the condition, as well as, to focus the research on mechanistic studies to understand the pathogenesis of the disease better.
Introduction
lights the need to develop a consensus based definition of the disease and calls for basic research to identify the IgM nephropathy (IgMN) is relatively a newly described, causes and pathogenesis of the condition. albeit controversial clinicopathologic entity which
The Pubmed (www.pubmed.gov) search was made on mainly presents an idiopathic nephrotic syndrome (INS) IgMN articles as the sole subject of the study or where it both in children and adults. This account reviews the constituted a significant number of cases in biopsy sedefinition of the disease, historical background, etiology, ries in the world literature written in English. Following pathogenesis, pathology, clinical manifestations, treatterms were used for the search: IgM nephropathy, renal ment and the prognosis of the condition. It also highbiopsy, native kidney, and transplanted kidney. A total of 41 articles were found. The studies had been reported from all parts of the world, most of them from North America, Canada, Finland, Taiwan, Hong Kong, Middle East and South Asia. A critical review of the relevant stud ies was made which formed the foundation of this review along with researchers` experience with the disease.
Definition
The major controversy on IgMN has resulted from the lack of a universally acceptable definition of the entity. The disease, like IgA nephropathy (IgAN), is defined by its immunohistologic features: the presence of immu noglobulin M (IgM) as the sole or dominant immuno globulin in the mesangial regions of the glomeruli in a diffuse (all glomeruli) and global (the entire glomerulus) distribution (1) (2) (3) (4) , positivity as the minimum threshold for the diagnosis of the disease (5) (6) (7) (8) . This has resulted in marked confusion and controversy in the lit erature on the unique nature of IgMN (1, 9) . There is an urgent need to develop a consensus based definition of the condition. Since, both the light microscopy (LM) and electron microscopy (EM) findings are highly variable, the entire effort should be directed to develop standard ization of the technique and the interpretation of immu nofluorescence (IF) study for this purpose.
History
Although, the first formal reporting of IgMN in litera ture is widely credited to the two independent research groups led by Cohen (2), and Bhasin(3), who reported 12 and 11 patients, respectively, in 1978 presenting with heavy proteinuria, the predominant IgM deposits in the glomeruli, in fact, were first described in renal biopsies in 1974 by Putte et al. (10) in patients with persistent or recur rent hematuria (HU). Soon after 1978, a series of publica tions were reported from England, other parts of Europe, Canada, Japan, and Taiwan (4, 5, 8, 9) . Interestingly, some of the largest and longest studies on the clinical course and natural history of the disease have been reported from Finland, Europe (11) (12) (13) . More recently, when the in terest in the disease has largely diminished in western countries, the disease is being reported more frequently from the centers in the developing countries (14-17).
Epidemiology
Like its definition, the epidemiology of the disease is fraught with controversies and confusion. There is no population based incidence or prevalence data on the disease in any parts of the world. Most studies on the in cidence of the disease report the frequency of the disease in renal biopsies performed on a variety of indications, most commonly the idiopathic nephrotic syndrome (INS). The reported frequency of IgMN in literature has varied widely from 2% to 18.5% (1) (2) (3) 18) . In fact, the fre quency indicated a rising trend during the early period of its recognition (2-5). The first two pioneering studies reported incidence of 2% and 6.1% respectively in their bi opsies (2, 3) . These reports were soon followed by a study of 23 (19) .
The precise basis for the wide variations in the preva lence of IgMN is not known but it may be related partially to varying biopsy indications, varying case definitions used in different studies, and the genetic or environmen tal factors (5).
Etiology
As of today, no causes are known for the development of the primary form of IgMN. However, the deposits of IgM in the glomeruli may be seen in a variety of systemic dis eases, such as systemic lupus erythematosus (SLE), rheu matoid arthritis, diabetes mellitus, paraproteinemia, and Alport's syndrome (19, 20) . The above conditions must be substituted by clinical and laboratory tests to diagnose primary IgMN.
Pathogenesis
An understanding of the disease mechanism is linked to etiology of the condition. For a disease like IgMN, where the etiology is unknown, the pathogenesis of the disease is also still largely unknown. Furthermore, very few studies have been conducted to elucidate the mecha nism of this condition. The major reason for this apathy is the reluctance of the western researchers to accept this disease as a separate entity (9) . Some studies have found elevated serum IgM or IgM immune complex concentra tions in patients with IgMN (5, 21). However, no struc tural or biochemical abnormalities of IgM molecule, as observed in IgA immunoglobulin, have been described yet. The few studies on the co-localization of the comple mentary components along with IgM have suggested classical immune complex mediated activation of the complementary cascade, in the glomerular mesangium leading to injury and the reaction to the injury (5). This hypothesis is supported by the frequent presence of C1q and C4 deposits along with IgM in glomerular mesangi um in the majority of cases, and the absence of properdin and factor B (5). Other studies, including the current one, have found C3 in the majority of cases , but C1q only in frequently (1) . The source and the nature of the antigens triggering immune complex formation is not known,
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Nephro-Urol Mon. 2012;4(4) but it is hypothesized that certain antigens in the food or environment which preferentially induce IgM response may be the culprits. Abnormalities of T-lymphocyte regu latory role or a disturbance in the mesangial cell clear ance of the passively trapped immune complexes have also been hypothesized (5) . There are no animal models of the disease, which have hampered the study of the dis ease in the laboratory.
Pathology
The diagnosis of IgMN, like all other glomerulopathies, depends on detailed pathologic evaluation of renal biop sy by LM, IF, and EM. Of these, the first two are essential, and the EM is optional. It confirms the LM and IF find ings. The pathologic findings need to be correlated with clinical and serological studies to exclude the secondary causes of IgM deposition. BOX shows the immunohisto pathological features commonly observed on renal biop sies in patients with IgMN.
Light Microscopy
In contrast to the consistent deposits of IgM on IF mi croscopy, the LM findings in IgMN are quite heteroge neous, as in IgAN and lupus nephritis. The spectrum of morphologic alterations encompasses the whole spec trum ranging from minor changes, to variable degrees of mesangial proliferation, usually of mild to moderate degree, to focal segmental glomerulosclerosis (FSGS) pat tern accompanied by adhesion formation with the Bow man's capsule (1, 5, 13) (Figure 1) . In a few reports small cellular crescents have also been observed (4, 22) . A case of IgMN has been observed in a female 11-year-old child with full blown crescentic glomerulonephritis (CresGN) (unpublished data). The most prevalent morphologic alteration reported, consists of mesangial proliferation, mostly of mild to moderate degree (1, 5) . In a minority of cases, severe mesangial proliferation with circumferen tial interpositioning of the expanded mesangium into the peripheral capillary walls with consequent splitting and tram-track appearance have also been reported (5, 22) . The minor changes on LM are the next frequent pat tern in most of the studies. It is difficult to distinguish this alteration from the minimal change disease (MCD) on LM examination alone and requires IF and EM to re solve the differential. This pattern has been reported in about one third of cases (1, 5, 13) . FSGS pattern as the morphologic expression of IgMN is the most controver sial feature. Many studies have excluded cases with this morphology from the IgMN category, while others have observed this lesion in a significant number of cases (1, 5) . These cases indicate global mesangial positivity of IgM in contrast to nonspecific, segmental trapping of IgM in the idiopathic form of FSGS. The previous reports on preva lence of this morphologic pattern in biopsies of IgMN show wide variation (4, 5, 13, 18) . The reported rates of this lesion have varied from 9 to 65.2% (1, 13) . Focal global sclerosis is also quite common (4). Some researchers have noted progression of IgMN cases with minor changes or mesangial proliferation into FSGS on repeated biopsies in a variety of cases (13, 23) .
Although most researches in progressive glomerular diseases are focused on glomerular alterations, stud ies have shown that alterations in the tubulointerstitial 
Electron microscopic findings
Minor changes or mesangialproliferation commensurate with light microscopic changes Fusion of foot processes, proportional to degree of proteinuria Electron dense deposits of variable density, a variable feature compartment are more important. Tubular atrophy and interstitial scarring are also commonly observed on renal biopsies of IgMN at the time of diagnosis and are usually mild (1, 13, 18, 20) . Moderate and severe tubular atrophy have been rarely reported (1, 13, 20) . Mild fibrointimal thickening of arteries has also been reported in a minor ity of cases (1, 13). 
Immunoflourescence

Electron Microscopy
There are very few studies on the ultrastructural fea tures of IgMN. In the majority of cases, no EM was done and the diagnosis was made solely on IF microscopy. The few studies that have carried out EM examination have noted small, granular to short linear, electron-dense de posits in the mesangium and paramesangium, along with variable degrees of mesangial cell proliferation and mesangial matrix expansion. Variable degrees of fu sion of foot processes commensurate with the degree of proteinuria have also been observed (4, 5) . The electrondense deposits have typically been of low volume and low density, and in many cases, rather ill-defined (4, 5, 24).
Clinical Features
The clinical manifestations of IgMN are highly variable. The disease occurs predominantly in children and young adults but it can occur at any age. An early mean age of onset has been reported in males as compared with fe males in one study (18) . Overall, the disease is slightly more common in males compared with females. How ever, some studies have found a female preponderance, especially in patients with HU (13) .
Clinically, the disease most commonly presentswith id iopathic NS in both children and adults (1, 4, 5, 13 ). The dis ease frequently presents with HU or asymptomatic uri nary abnormalities (AUA) (13) . However, the majority of nephrologists around the world do not undertake renal biopsy in patients with the later manifestations, which accounts for the low frequency of patients with these manifestations. Isolated HU or proteinuria-hematuria (PU-HU) constituted almost half of biopsy indications in some previous reports (13) . This may have implications for the severity of the pathological lesions observed on renal biopsy and the long term outcome of disease. Some authors have observed that patients with HU, especially adult females, have a good prognosis, compared with patients with NS or proteinuria (PU) (13) . It has been ob served, however, that IgMN in children are mostly pre sented as INS rather than HU or PU, as indicated by Myl limaki et al. (13) , in which 32 of 36 children with IgMN presented as NS and only four children presented with non nephrotic proteinuria and none presented PU-HU or HU.
Hypertension is found in a significant minority of pa tients at presentation or biopsy (1, 4, 5) . Its prevalence in creases with increasing duration of the disease approach ing 50% at 15 years of follow-up (13).
Natural History and Prognosis
The natural history and prognosis of IgMN, like its pre sentation and morphology, are also quite varied. There are multiple reasons for that. Apart from the variable length of follow-up of the patients, the lead-time diagnos tic bias, and variable case ascertainment criteria are also partly responsible for this variable clinical evolution of the disease. The first two studies on IgMN did not report progression to ESRD, probably because of short follow-up period. The rate of ESRD development in the other report ed studies has varied widely from four to 23 percent (13, 16, 20) . The highest rate of 23 percent has been reported in the largest and longest follow-up study from Finland, in which renal failure was observed in 35% of cases in 15 years of follow-up, and ESRD developed in 23% of cases (13) . These variable rates of ESRD development mostly re flect variable periods of follow up (20) . The later authors also investigated for clinical and pathological prognostic factors leading to renal failure or ESRD. In multivariate analysis, hypertension was the only factor that predicted renal failure; on the other hand, none of the analyzed multiple factors were predicting ESRD. In the authors' opinion this might have resulted from a small number of patients reaching ESRD in their study (13) . An Indian study on adults and adolescents found that proteinuria and hypertension were predicting factors among the clinical and laboratory parameters, and FSGS, tubular atrophy and interstitial fibrosis among the pathological features (18) . Another study identified microscopic HU, extent of mesangial proliferation, and global glomeru losclerosis as independent prognostic markers of multi variate analysis (25) .
One important complication of IgMN is the transition of usual mesangial proliferative GN into the morpholog ic expression of FSGS. The later development can be only diagnosed in repeated biopsies and is associated with progressive disease. This complication has been studied only in a few reports (13, 23) .
Treatment
Due to unknown etiology and pathogenesis of the con dition, there is no specific treatment. There are also no randomized controlled trials on the treatment of IgMN. Corticosteroids constitute the mainstay of treatment as in MCD or primary FSGS (9) . The steroid response pat tern in IgMN varies considerably among the reported studies; the reported steroid resistance varies from 0 to 52% (9) . The highest steroid resistance of 66% has been recently reported by Mokhtar (Saudi Arabia) (20) . Border (9) reviewed nine affirmative papers on IgMN and found a mean steroid resistance of 28%. Steroid resistance was also found in about one third of the children with INS (1). The above studies indicate that IgMN responds less to steroids compared to typical MCD, and favors the hypoth esis that IgMN is distinct from MCD (1, 13). Besides, not many investigators have found significant differences in clinicopathological or steroid response pattern among these diseases (24, (26) (27) (28) .
There is little data on the use and response rates of im munosuppressive agents in patients with IgMN(9, 13). Oral cyclophosphamide has been used in a number of studies with response rates of up to 50% (13, 16) . The data on cyclosporine usage is further scanty, with only occa sional reports describing a favorable response in steroid dependent IgMN patients (16) . Recurrent disease after renal transplantation has been successfully treated with anti-CD antibodies (rituximab), in combination with plasma exchanges, and immunoglobulins (29, 30) .
Conclusions
In conclusion, IgMN is an important, but neglected cause of renal morbidity in both children and adults in many parts of the world. It shows a spectrum of mor phologic changes ranging from minor changes to FSGS. Immunofluorescence is necessary for its diagnosis. Clini cally, a poor response to steroid therapy distinguishes this disease from MCD. Further longitudinal studies are needed to clarify the status of the disease among the pri mary glomerulopathies. There is an urgent need for col laborative studies between health centers in the devel oping countries, where the disease is common, and the developed world, where resources and infrastructure for research are fully developed. Such studies can elucidate the etiology and pathogenesis of this disease and lead to development of effective therapeutic regimens.
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